Abstract:Though significant strides in tumorigenic comprehension and therapy modality have been witnessed over the past decades, glioma remains one of the most common and malignant brain tumors characterized by recurrence, dismal prognosis, and therapy resistance. Immunotherapy advance holds promise in glioma recently. However, the efficacy of immunotherapy varies among individuals with glioma, which drives researchers to consider the modest levels of immunity in the central nervous system, as well as the immunosuppressive tumor immune microenvironment (TIME). Considering the highly conserved property for sustaining energy homeostasis in mammalian cells and repeatedly reported links in malignancy and drug resistance, autophagy is determined as a cutting angle to elucidate the relations between glioma and the TIME. In this review, heterogeneity of TIME in glioma is outlined along with the reciprocal impacts between them. In addition, controversies on whether autophagy behaves cytoprotectively or cytotoxically in cancers are covered. How autophagy collapses from its homeostasis and aids glioma malignancy, which may depend on the cell type and the cellular context such as reactive oxygen species (ROS) and adenosine triphosphate (ATP) level, are briefly discussed. The consecutive application of autophagy inducers and inhibitors may improve the drug resistance in glioma after overtreatments. It also highlights that autophagy plays a pivotal part in modulating glioma and the TIME, respectively, and the intricate interactions among them. Specifically, autophagy is manipulated by either glioma or tumor-associated macrophages to conform one side to the other through exosomal microRNAs and thereby adjust the interactions. Given that some of the crosstalk between glioma and the TIME highly depend on the autophagy process or autophagic components, there are interconnections influenced by the status and well-being of cells presumably associated with autophagic flux. By updating the most recent knowledge concerning glioma and the TIME from an autophagic perspective enhances comprehension and inspires more applicable and effective strategies targeting TIME while harnessing autophagy collaboratively against cancer.

Autophagy Modulation and Its Implications on Glioblastoma Treatment

Autophagy Machinery in Glioblastoma: the Prospect of Cell Death Crosstalk and Drug Resistance with Bioinformatics Analysis.

Regulation of autophagy as a therapeutic option in glioblastoma

Breaking Bad: Autophagy Tweaks the Interplay Between Glioma and the Tumor Immune Microenvironment

Autophagy: a strategy for malignant gliomas' resistance to therapy.

Role of autophagy in modulating tumor cell radiosensitivity: Exploring pharmacological interventions for glioblastoma multiforme treatment

Deciphering the Role of Autophagy in Treatment of Resistance Mechanisms in Glioblastoma

Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors

Autophagy and Glioma Treatment

Autophagy in glioblastoma: A mechanistic perspective

Progress in effect of autophagy on gliomas radiation therapy and chemotherapy and molecular regulating mechanism

Autophagy Regulators As Potential Cancer Therapeutic Agents: A Review

Regulation of autophagy in tumor cells and application of targeting autophagy in cancer

Autophagy Regulators in Cancer

Autophagy Paradox: Strategizing Treatment Modality in Melanoma

The Role of Autophagy in Sensitizing Malignant Glioma Cells to Radiation Therapy

Autophagy Modulation in Cancer Therapy: Challenges Coexist with Opportunities

Molecular Machinery of Autophagy and Its Implication in Cancer.

Nano delivery of natural substances as prospective autophagy modulators in glioblastoma

Autophagy in Cancer Therapy: Progress and Issues

Regulation of autophagy by non-coding RNAs in human glioblastoma